
Prestige Consumer Healthcare Inc.: financial statements
Price
$49.63
November 20, 2026Market cap $2.4B
What Ploutos Investor adds for Prestige Consumer Healthcare
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
| Line | FY2024 | FY2025 | FY2026 | Average a year |
|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | |
| Cost of revenue | $501M | $503M | $493M | |
| Gross profit | $624M | $634M | $596M | |
| Operating income | $342M | $337M | $309M | |
| Net income | $209M | $215M | $190M | |
| Earnings per share | $4.17 | $4.29 | $3.91 | |
| Earnings per share, basic | $4.21 | $4.32 | $3.93 | |
| Margins | ||||
| Gross margin | 55.5% | 55.8% | 54.7% | |
| Operating margin | 30.4% | 29.6% | 28.4% | |
| Net margin | 18.6% | 18.9% | 17.5% | |
Financial statements
PBH's revenue, profits and cash flows from FY2010 to FY2023, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
By segment
Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.
- North American OTC Healthcare
- International OTC Healthcare
- FY2024: North American OTC Healthcare $958M, International OTC Healthcare $167M
- FY2025: North American OTC Healthcare $960M, International OTC Healthcare $178M
- FY2026: North American OTC Healthcare $914M, International OTC Healthcare $175M
| Segment | FY2024 | FY2025 | FY2026 | Share FY2026 |
|---|---|---|---|---|
| North American OTC Healthcare | $958M | $960M | $914M | 84% |
| International OTC Healthcare | $167M | $178M | $175M | 16% |
By segment
PBH's revenue by segment from FY2014 to FY2023, 10 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the XBRL of 11 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
When the debt falls due
Mar 31, 2026Due within 2 years
$400M
Total falling due
$1.0B
Total in the ladder $1.0B, from the annual report dated March 31, 2026. Principal of loans and bonds, without leases and interest. The filing
- 3/2027: $0
- 3/2028: $400M
- 3/2029: $0
- 3/2030: $0
- 3/2031: $0
- 3/2032 on: $600M
The ladder at each year end
| Year | 1 yr | 2 yrs | 3 yrs | 4 yrs | 5 yrs | Later |
|---|---|---|---|---|---|---|
| FY2026 | $0 | $400M | $0 | $0 | $0 | $600M |
| FY2025 | $0 | $0 | $400M | $0 | $0 | $600M |
| FY2024 | $0 | $0 | $0 | $400M | $135M | $600M |
The ladder at each year end
When PBH's debt fell due, as each annual report set it out, from FY2013 to FY2023, 11 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Leases
Mar 31, 2026Operating leases
$28M
Finance leases
$21M
- Average discount rate
- 6.4%
- Lease cost for the year
- $7.9M
The liability is the present value of the rent still to pay, at March 31, 2026. It is not counted in the ladder's debt. The filing
Operating lease payments by year
Lease liability by year
Leases
PBH's leases from FY2019 to FY2023, 5 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Pension plans
Mar 31, 2026Defined-benefit pensions
0%funded
Deficit $3.1M.
The obligation is the present value of the pensions employees have already earned, at March 31, 2026. A deficit is the company's to fill with contributions. The filing
Pensions funded, by year
Pensions funded, by year
How far PBH's pension plans were funded, from FY2016 to FY2023, 8 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Goodwill by segment
Mar 31, 2026Total goodwill
$581M
- North American OTC Healthcare$551M95%
- International OTC Healthcare$30M5%
Goodwill is what the company paid in acquisitions above the value of what it bought, at March 31, 2026. If an acquisition earns less, the goodwill is impaired and earnings fall. The filing
Goodwill by year
Goodwill by year
PBH's goodwill from FY2012 to FY2023, 12 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the statutory to the effective tax rate, FY2026
Mar 31, 2026Statutory rate
21.0%
Effective rate
26.1%
The company paid 26.1% in tax on its profit, 5.1 points above the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
State and local taxes
+4.5 pts
Foreign rate differential · Australia
+1.0 pts
Executive pay deduction limit
+0.5 pts
Foreign rate differential · Other countries
-0.5 pts
Smaller lines (7)
-0.4 pts
Effective rate
26.1%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
Effective tax rate by year
The tax rate PBH paid on its profit, from FY2011 to FY2023, 13 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Earnings quality
How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.
Where the change in earnings per share came from
Diluted earnings per share went from $4.29 in the fiscal year to Mar 31, 2025 to $3.91 in the year to Mar 31, 2026, a change of -$0.38.
Measured by size, 33.8% of the movement came from outside sales and operating margin: interest and other items, the tax rate, what went to others and the share count.
- -$0.22
- -$0.20
- +$0.01
- -$0.09
- +$0.11
Earnings per share is split as sales times operating margin, plus interest and other items, after tax, times the part that goes to the common shareholders, divided by the diluted share count. Each source's part is its average effect over every order in which the six can change, so the parts add up exactly to the change. From the annual reports; net income over the diluted count matches the earnings per share the company filed within 2%.
Receivables and inventory against sales
In the quarter to Sep 30, 2026, sales were +22.7% on the same quarter a year earlier, and receivables +22.7%. Inventory was +12.7%, against +33.7% for the cost of sales.
- a year earlier 66 days
- 66 days
- a year earlier 118 days
- 100 days
Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.
Allowance for doubtful accounts
The allowance for receivables that may not be collected was 9.0% of gross receivables at Sep 30, 2026, against 8.7% a year earlier.
- a year earlier $19M
- $24M
Taxes: deferred and paid
The deferred part was 33.8% of the tax charge in the year to Mar 31, 2026. The rows show the last 3 years.
Cash taxes paid were 102.9% of the current tax charge in the year to Mar 31, 2026.
- Deferred share, year to Mar 31, 2026$23M of $67M
- 33.8%
- Deferred share, year to Mar 31, 2025$14M of $70M
- 20.7%
- Deferred share, year to Mar 31, 2024$23M of $67M
- 34.6%
- $46M paid, $45M current
- 102.9%
When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.
A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Prestige Consumer Healthcare's filings show?
These are Prestige Consumer Healthcare's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did PBH have in FY2026?
Prestige Consumer Healthcare had revenue of $1.1B and net income of $190M in fiscal FY2026, a net margin of 17.5%.
How much debt does PBH have?
On March 31, 2026 Prestige Consumer Healthcare had total assets of $3.5B, debt of $994M and shareholders' equity of $1.9B.
How much free cash flow does PBH have?
In fiscal FY2026 Prestige Consumer Healthcare had cash from operations of $258M and spent $11M on capital expenditure, leaving $246M of free cash flow.
Where are the figures from?
From Prestige Consumer Healthcare Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.